EGCG degraded PARP by downregulating P-Akt, Bcl-2, and P-gp, suppressing the vitality of drug-resistant cancer cells and decreasing the stemness of tumor cells, resulting in more sensitivity of cancer cells to TMZ and apoptosis (200). The gene discussed is BCL2; the disease is cancer.